AstraZeneca had placed its immunotherapy Imfinzi (durvalumab) at the centre of its efforts to rebuild its sales – but after a shock failure last year in first line lung cancer, the drug has
Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug could revolutionise treatment when combined with chemotherapy.
